News & Updates
Filter by Specialty:
![Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF](https://sitmspst.blob.core.windows.net/images/articles/adding-cyclophosphamide-to-glucocorticoid-therapy-may-up-mortality-risk-in-ipf-d70306ee-ff57-4875-b47c-81c3762a90bc-square.jpg)
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
24 Sep 2021![SARS-CoV-2 lurks in small airborne particles](https://sitmspst.blob.core.windows.net/images/articles/sars-cov-2-lurks-in-small-airborne-particles-2373817c-2c51-459e-bebc-f766e4f6ee67-square.jpg)
SARS-CoV-2 lurks in small airborne particles
Investigations into the role of small aerosol particles in COVID-19 transmission suggest that SARS-CoV-2 may be an airborne hazard. A recent medRxiv preprint study from Singapore adds to this body of evidence.
SARS-CoV-2 lurks in small airborne particles
24 Sep 2021![The air we breathe in the workplace: Is it safe?](https://sitmspst.blob.core.windows.net/images/articles/occupational-asthma-ee22e518-9f8a-491b-a9dd-6d8ec32c453d-square.jpg)
The air we breathe in the workplace: Is it safe?
What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.
The air we breathe in the workplace: Is it safe?
24 Sep 2021![Tofacitinib may promote HBV reactivation in certain RA patients](https://sitmspst.blob.core.windows.net/images/articles/fotolia109029242-24d9afb7-b196-46de-b707-44c976c605f8-square.jpg)
Tofacitinib may promote HBV reactivation in certain RA patients
Use of tofacitinib for rheumatoid arthritis (RA) may lead to reactivation of hepatitis B virus (HBV), especially among hepatitis B surface antigen-positive (HBsAg+) and HBsAg-negative/hepatitis B core antibody-positive (HBsAg–/HBcAb+) patients, according to a study from Taiwan.